^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial

Published date:
11/17/2020
Excerpt:
...CNA in CDKN2A (12%) and CDKN2B (11%) were associated with improved PFS and OS clinical activity in the A + nP arm vs the P + nP arm (HR PFS, 0.43-0.44 and HR OS, 0.47, respectively).
Secondary therapy:
albumin-bound paclitaxel
Trial ID: